Essential role of prostaglandin E$_2$ and the EP3 receptor in lymphatic vessel development during zebrafish embryogenesis

Ryo Iwasaki$^1$, Kyoshiro Tsuge$^1$, Koichiro Kishimoto$^1$, Yuta Hayashi$^1$, Takuya Iwana$^1$, Hirofumi Hohjoh$^1$, Tomoaki Inazumi$^{1,2}$, Atsuo Kawahara$^3$, Soken Tsuchiya$^{1,2}$ & Yukihiko Sugimoto$^{1,2}$

Lymphatic endothelial cells arise from the venous endothelial cells in embryonic lymphatic development. However, the molecular mechanisms remain to be elucidated. We here report that prostaglandin (PG) E$_2$ plays essential roles in the embryonic lymphatic development through the EP3 receptor, one of the PGE$_2$ receptors. Knockdown of the EP3 receptor or inhibition of cyclooxygenases (COX; rate-limiting enzymes for PG synthesis) impaired lymphatic development by perturbing lymphatic specification during zebrafish development. These impairments by COX inhibition were recovered by treatment with sulprostone (EP1/3 agonist). Knockdown of the EP3 receptor further demonstrated its requirement in the expression of sex determining region Y-box 18 (sox18) and nuclear receptor subfamily 2, group F, member 2 (nr2f2), essential factors of the lymphatic specification. The EP3 receptor was expressed in the posterior cardinal vein (region of embryonic lymphatic development) and the adjacent intermediate cell mass (ICM) during the lymphatic specification. COX1 was expressed in the region more upstream of the posterior cardinal vein relative to the EP3 receptor, and the COX1-selective inhibitor impaired the lymphatic specification. On the other hand, two COX2 subtypes did not show distinct sites of expression around the region of expression of the EP3 receptor. Finally, we generated EP3-deficient zebrafish, which also showed defect in lymphatic specification and development. Thus, we demonstrated that COX1-derived PGE$_2$-EP3 pathway is required for embryonic lymphatic development by upregulating the expression of key factors for the lymphatic specification.

The lymphatic system is a major component of the vertebrate vasculature and plays pivotal roles in the collection of interstitial fluid, absorbance of dietary lipids, and trafficking of immune cells. Development of the lymphatic system begins in the early developmental stages, and lymphatic endothelial cells develop from endothelial cells in the posterior cardinal vein. Vascular endothelial growth factor c (vegfc) and its receptor, fms-related tyrosine kinase 4 (flt4; also known as vascular endothelial growth factor receptor 3, vegfr3) are key factors for lymphatic specification. Vegfc released by the dorsal aorta induces the lymphatic specification through binding toflt4 expressed in venous endothelial cells. Sex determining region Y-box 18 (sox18), a member of sox transcription factor family, is also essential for the lymphatic specification through the induction of transcriptional factors, such as nuclear receptor subfamily 2, group F, member 2 (nr2f2; also known as COUP transcription factor 2, COUP-TFII). Nr2f2 controls the expression of lymphatic genes, such as lymphatic vessel endothelial hyaluronan receptor 1b (lyve1b; a lymphatic marker). Additionally, apelin (apln), collagen and calcium binding EGF domains 1 (ccbe1), and wingless-type MMTV integration site family, member 5b (wnt5b) (secreted...
proteins) were reported to promote lymphatic development. On the other hand, bone morphogenetic protein 2b (bmp2b) was shown to negatively modulate the development of lymphatic endothelial cells.

Prostaglandin (PG) E2 is an arachidonic metabolite that is synthesized via a pathway with cyclooxygenase (COX) as the rate-limiting enzyme. PGE2 has been shown to exert a variety of actions by binding to four specific G-protein-coupled receptors (EP1, EP2, EP3, and EP4) on the plasma membrane of neighboring cells in humans and mice. The EP1 receptor is coupled to Gq to increase intracellular Ca2+ concentrations. The EP2 and EP4 receptors are coupled to Gs and increase intracellular CAMP concentrations via the activation of adenyl cyclase. The EP3 receptor is coupled to Gi, and mediates the inhibition of adenyl cyclase and the upregulation of intracellular Ca2+ concentrations. The formation of lymphatic vessels is known to occur during not only embryogenesis but also the progression of various cancers, and COX2-derived PGE2 was found to facilitate lymphangiogenesis during tumor development through the EP3 receptor in mice. In addition, PGE2 was shown to accelerate the formation of lymphatic vessels through the EP3 receptor in granulation tissues. These data suggest the possibility that the PGE2-EP3 pathway plays important roles in the formation of lymphatic vessels. However, it remains unknown whether the PGE2-EP3 pathway is involved in the development of lymphatic vessels during embryogenesis.

To identify the role of the PGE2-EP3 pathway in lymphatic vessel development during embryogenesis, we used zebrafish as a model organism, because zebrafish embryos are optically clear and undergo rapid early development outside the maternal body. In addition, zebrafish share many similarities in their molecular mechanisms of lymphatic vessel formation with other vertebrates, and express three COX subtypes (COX1, COX2a, and COX2b) and eight PGE2 receptor subtypes (EP1a, EP1b, EP2a, EP2b, EP3, EP4a, EP4b, and EP4c). Here, we report novel functions of the PGE2-EP3 pathway in the formation of lymphatic vessels during early development.

Results

The PGE2-EP3 pathway is involved in lymphatic vessel formation during early development. To investigate whether the PGE2-EP3 pathway regulates lymphatic vessel formation in embryogenesis, we analyzed the effects of EP3 receptor knockdown on zebrafish lymphatic development using Tg(fli1a:egfp) embryos, in which both blood and lymphatic vessels are labeled. We used two splice-blocking morpholino antisense oligos (MOs), EP3 MO1 and MO2 (Supplementary Fig. S1A, Supplementary Table S1). Quantitative analysis showed that injection of EP3 MO1 or MO2 both markedly decreased the mature mRNA expression level of the EP3 receptor at 24 hours post fertilization (hpf) (Supplementary Fig. S1B). To evaluate lymphatic vessel formation, we analyzed the parachordal lymphoblast (PL) at the horizontal myoseptum, which is commonly used to study lymphatic development in zebrafish.

In control (Cont) MO-injected embryos, the PL was fully formed in most of the segments at 52 hpf (Fig. 1A,B). On the other hand, PL formation was severely impaired in morphants injected with EP3 MO1 or MO2 (Fig. 1A), and the ratio of PL-positive segments was also significantly reduced in these morphants (Fig. 1B). We then investigated whether indomethacin, a non-selective COX inhibitor, induces lymphatic vessel defects. In vehicle-treated embryos, PL was normally formed in the horizontal myoseptum at 52 hpf. On the other hand, treatment with indomethacin inhibited PL formation and significantly reduced the ratio of PL-positive segments (Fig. 1C,D). This effect of indomethacin was substantially recovered by cotreatment with sulprostone, an EP1 agonist (Fig. 1C,D). Furthermore, we investigated the formation of thoracic duct (TD), which is located immediately ventral to the dorsal aorta in the trunk, at 5 days post fertilization (dpf) (Fig. 1E,F). In Cont MO-injected embryos, the TD was fully formed in most of the segments. On the other hand, TD formation was severely impaired in morphants injected with EP3 MO1 and MO2 (Fig. 1E), and the ratio of TD-positive segments was significantly reduced in the EP3 MO1-injected morphants (Fig. 1F). These results indicated that the PGE2-EP3 pathway plays an important role in lymphatic vessel formation during early development.

The PGE2-EP3 pathway is required for lymphatic specification from venous to lymphatic endothelial cells. Lymphatic endothelial cells are generated from pre-existing endothelial cells of the posterior cardinal vein from approximately 24 to 36 hpf, and subsequently sprout from the posterior cardinal vein after 36 hpf and migrate to colonize embryonic tissues. To identify the lymphatic development process in which the PGE2-EP3 pathway is involved, we performed time-dependent inhibition of PG synthesis by treatment with indomethacin for a limited time (Fig. 2A). There was no significant difference in the ratios of PL-positive segments between vehicle treatment and indomethacin treatment from 12 to 24 hpf, when the posterior cardinal vein develops. On the other hand, indomethacin treatment from 24 to 36 hpf significantly reduced the ratio of PL-positive segments. The degree of reduction by the treatment from 24 to 36 hpf was equivalent to that by the treatment from 24 to 60 hpf. These data suggest the importance of the PGE2-EP3 pathway in the lymphatic specification process. Therefore, to determine whether the PGE2-EP3 pathway acts during the first steps of lymphatic development, we analyzed the expression levels of lyve1b, which is a lymphatic marker. Compared with control morphants, EP3 receptor morphants had significantly lower expression levels of lyve1b at both 24 and 36 hpf (Fig. 2B). Whole-mount in situ hybridization (WISH) analysis demonstrated that lyve1b was expressed around the posterior cardinal vein in Cont MO-injected embryos at both 24 and 36 hpf (Fig. 2C,D). By contrast, embryos injected with EP3 MO1 showed substantial decreases in lyve1b-derived signals around the posterior cardinal vein at both time points (Fig. 2C,D). Embryos treated with indomethacin also showed decreased expression levels of lyve1b at 24 hpf (Fig. 2E). This effect of indomethacin was significantly recovered by cotreatment with sulprostone but not ONO-AE1-259 (an EP2 agonist) or ONO-AE1-329 (an EP4 agonist) (Fig. 2E). WISH analysis of embryos at 24 hpf demonstrated that indomethacin markedly reduced lyve1b-derived signals around the posterior cardinal vein, where lyve1b-derived signals were observed in vehicle-treated embryos (Fig. 2F). Lyve1b-derived signals that were decreased by indomethacin were recovered to the levels similar to that of vehicle-treated embryos by the cotreatment of sulprostone (Fig. 2F). These results indicated that the PGE2-EP3 pathway contributes to the formation of lymphatic vessels by regulating the lymphatic specification, which is the first step of lymphatic development during embryogenesis.
Figure 1. Role of the PGE2-EP3 pathway in lymphatic vessel formation. (A) Tg(fli1a:egfp) embryos were injected with Cont MO, EP3 MO1, or MO2. Images of the trunks were taken at 52 hpf. (B) The ratio of PL-positive segments in nine consecutive segments of (A) was quantitated. Each value represents the mean ± SEM (N = 3–4). (C) Tg(fli1a:egfp) embryos were treated with vehicle (Veh) or indomethacin (Indo; 100 μM) in the absence or presence of sulprostone (Sulp; 1 μM) from 0 to 52 hpf. Images were taken at 52 hpf. (D) The ratio of PL-positive segments in nine consecutive segments of (C) was quantitated. Each value represents the mean ± SEM (N = 3). (E) Tg(fli1a:egfp) embryos were injected with Cont MO, EP3 MO1, or EP3 MO2. Images of the trunks were taken at 5 dpf. (F) The ratio of TD-positive segments in eight consecutive segments of Cont MO- or EP3 MO1-injected morphants was quantitated. Each value represents the mean ± SEM (N = 5–9). **P < 0.01 vs Cont MO. DA: dorsal aorta; ISV: intersomitic vessel; PL: parachordal lymphangioblast; TD: thoracic duct. The PL is indicated by arrowheads, and the TD is indicated by arrows. The number at the bottom right of each panel indicates the number of embryos demonstrating the phenotype shown in the panel over the total number of embryos analyzed in a representative experiment.
Figure 2. Role of the PGE₂-EP3 pathway in the lymphatic specification from venous to lymphatic endothelial cells. (A) Tg(fli1a:egfp) embryos were treated with Veh or Indo (100μM) for the indicated times. The ratio of PL-positive segments at 60 hpf was quantified. Each value represents the mean ± SEM (N = 5). **P < 0.01 vs Veh. (B) Relative expression levels of lyve1b were quantified by RT-qPCR in morphants at 24 and 36 hpf. Values are shown relative to the value obtained with Cont MO at 24 hpf. Each value represents the mean ± SEM (N = 3–4) *P < 0.05, **P < 0.01 vs Cont MO at each corresponding time. (C,D) Expression of lyve1b was analyzed by WISH in morphants at 24 hpf (C) and 36 hpf (D). (E,F) Zebrafish embryos were treated with Veh or Indo (100μM) in the absence or presence of EP agonists (10μM) from 0 to 24 hpf. The expression level of lyve1b was quantified by RT-qPCR (E). The values are shown relative to the value obtained with Veh. Each value represents the mean ± SEM (N = 3–4). Expression of lyve1b was analyzed by WISH at 24 hpf (F). The number at the bottom right of each panel indicates the number of embryos demonstrating the phenotype shown in the panel over the total number of embryos analyzed in a representative experiment.
Expression levels of genes involved in the lymphatic specification.

To analyze the function of the PGE2-EP3 pathway in the lymphatic specification, we investigated the mRNA expression level of various genes (vegfc, flt4, sox18, nr2f2, apln, ccbe1, wnt5b, and bmp2b) crucially involved in the lymphatic specification4–10,14–17. By reverse transcription-quantitative PCR (RT-qPCR), we analyzed the expression levels of these genes in EP3 receptor morphants at 24 and 36 hpf (Fig. 3A–H), which are early and late phases of lymphatic specification, respectively. At both 24 and 36 hpf, expression levels of sox18 were significantly decreased in EP3 receptor morphants compared with control morphants (Fig. 3C). Expression levels of nr2f2 at 36 hpf were also significantly decreased in EP3 receptor morphants, although expression levels of nr2f2 at 24 hpf did not change (Fig. 3D). There was no significant difference in the expression levels of vegfc, flt4 (also known as a vein marker at 24 hpf), apln, ccbe1, wnt5b, and bmp2b (Fig. 3A,B,E–H). Because nr2f2 is expressed in not only the posterior cardinal vein but also the cranial and spinal cord10, we then examined the expression of nr2f2 around the posterior cardinal vein at 24 and 36 hpf by WISH analysis (Fig. 3I,J). Signals of nr2f2 were detected in the posterior cardinal vein and spinal cord in the trunk of Cont MO-injected embryos. In the trunk of EP3 MO1-injected embryos, nr2f2-derived signals were decreased only in the posterior cardinal vein but not the spinal cord, specifically in 36 hpf but not 24 hpf. These data indicated that the EP3 receptor plays important roles in the expression of sox18 and nr2f2 in the lymphatic specification.

Expression levels of genes involved in the lymphatic specification. To analyze the function of the PGE2-EP3 pathway in the lymphatic specification, we investigated the mRNA expression level of various genes (vegfc, flt4, sox18, nr2f2, apln, ccbe1, wnt5b, and bmp2b) crucially involved in the lymphatic specification4–10,14–17. By reverse transcription-quantitative PCR (RT-qPCR), we analyzed the expression levels of these genes in EP3 receptor morphants at 24 and 36 hpf (Fig. 3A–H), which are early and late phases of lymphatic specification, respectively. At both 24 and 36 hpf, expression levels of sox18 were significantly decreased in EP3 receptor morphants compared with control morphants (Fig. 3C). Expression levels of nr2f2 at 36 hpf were also significantly decreased in EP3 receptor morphants, although expression levels of nr2f2 at 24 hpf did not change (Fig. 3D). There was no significant difference in the expression levels of vegfc, flt4 (also known as a vein marker at 24 hpf), apln, ccbe1, wnt5b, and bmp2b (Fig. 3A,B,E–H). Because nr2f2 is expressed in not only the posterior cardinal vein but also the cranial and spinal cord10, we then examined the expression of nr2f2 around the posterior cardinal vein at 24 and 36 hpf by WISH analysis (Fig. 3I,J). Signals of nr2f2 were detected in the posterior cardinal vein and spinal cord in the trunk of Cont MO-injected embryos. In the trunk of EP3 MO1-injected embryos, nr2f2-derived signals were decreased only in the posterior cardinal vein but not the spinal cord, specifically in 36 hpf but not 24 hpf. These data indicated that the EP3 receptor plays important roles in the expression of sox18 and nr2f2 in the lymphatic specification.
**Figure 4.** EP3 receptor mRNA is expressed in the posterior cardinal vein and the neighboring ICM. (A,B) Regions of expression of marker genes and the EP3 receptor were analyzed by WISH at 24 hpf (A) and subsequently by microscopic examination of their cross-sections (B). Arrowheads indicate the regions where the signals derived from each gene were observed.

**COX1-derived PGE₂ regulates the lymphatic specification through the EP3 receptor.** We performed WISH analysis to identify the sites of EP3 receptor expression during the lymphatic specification. As previously reported, EP3 receptor-derived signals were detected around blood vessels of the trunk at 24 hpf (Fig. 4A). To analyze these expression sites in more detail, we compared the signals of the EP3 receptor with those of several tissue markers at 24 hpf, namely, hes-related family bHLH transcription factor with YRPW motif 2 (hey2; an aorta marker)⁴⁴, flt4 (a vein marker)⁴⁵, and GATA binding protein 1a (gata1a; an erythrocyte progenitor marker)⁴⁷, which is reported to be exclusively expressed in the intermediate cell mass (ICM) between the dorsal aorta and the posterior cardinal vein at this developmental stage⁴⁸. The signals of the EP3 receptor were located ventral to those of hey2 and around those of flt4 and gata1a (Fig. 4A). Furthermore, we made transverse sections of these embryos that were subjected to WISH analysis (Fig. 4B). As previously reported, hey2-derived signals were detected under the notochord in transverse sections. Signals of flt4 were located in a more ventral region than signals of hey2, and signals of gata1a were observed in a region between those of hey2 and flt4. EP3 receptor-derived signals appeared to be located in the region with both flt4-derived and gata1a-derived signals. These results indicated that the EP3 receptor is expressed in the ICM and the posterior cardinal vein, where lymphatic endothelial cells are generated.

COX are rate-limiting enzymes for the biosynthesis of PGE₂. As zebrafish have three subtypes of COX (COX1, COX2a, and COX2b), we tried to identify the specific COX subtypes involved in the lymphatic specification. We first performed WISH analysis at 24 hpf to identify the region of expression of each COX subtype during the lymphatic specification. COX1-derived signals were detected in the region more upstream of the posterior cardinal vein relative to EP3 receptor-derived signals (Fig. 5A). On the other hand, COX2a- and COX2b-derived distinctive signals were not detected in the trunk of zebrafish embryos (Fig. 5A). To clarify whether COX1 is involved in the lymphatic specification, we treated zebrafish embryos with a COX1-selective inhibitor, SC-560, and investigated the expression levels of lyve1b at 24 hpf using WISH analysis. SC-560 diminished lyve1b-derived signals around the posterior cardinal vein (Fig. 5B). The decrease in lyve1b-derived signals was recovered by cotreatment with sulprostone (Fig. 5B). These results suggested that COX1-derived PGE₂ plays important roles in the lymphatic specification from venous to lymphatic endothelial cells during early development.

**Impairment of lymphatic specification and development by EP3 receptor deficiency.** To confirm the role of the EP3 receptor in the lymphatic specification, we finally generated EP3 receptor-deficient (EP3−/−) zebrafish using transcription activator-like effector nucleases (TALEN)⁴⁹. Sequencing analysis showed that a stop codon was introduced into the transmembrane II region of the wild-type EP3 receptor by the deletion of seven base-pairs in transmembrane I (Fig. 6A). EP3+/− and EP3−/− zebrafish were born at approximately expected Mendelian ratio and were viable (Fig. 6B). We then performed the Ca²⁺ mobilization assay to confirm whether this deletion actually results in a loss of the function of the EP3 receptor. Although HeLa cells transfected with a construct encoding the wild-type EP3 receptor dose-dependently induced Ca²⁺ mobilization by sulprostone, HeLa cells transfected with a construct encoding the mutant EP3 receptor did not respond to sulprostone (Fig. 6C). Subsequently, we investigated the expression levels of lyve1b in EP3+/− and EP3−/− zebrafish to evaluate the effects of EP3 receptor deficiency on the lymphatic specification. Compared with EP3+/− zebrafish, EP3−/− zebrafish but not EP3+/− zebrafish had significantly lower expression levels of lyve1b at 24 hpf (Fig. 6D). Additionally, WISH analysis showed that the expression levels of lyve1b around the posterior cardinal vein were remarkably decreased in EP3−/− zebrafish but not EP3+/− zebrafish at 36 hpf (Fig. 6E). Finally, we investigated the expression of lyve1b at 52 hpf using WISH analysis to analyze PL formation in EP3−/− zebrafish (Fig. 6F). In EP3−/− zebrafish, lyve1b signals were detected in the horizontal myoseptum, indicating adequate PL formation. On the other hand, signals of lyve1b were not detected in EP3−/− zebrafish, indicating failure of PL formation. These results indicated the importance of EP3 receptor expression in lymphatic specification and development. Thus, the defects of lymphatic specification and development observed upon EP3 receptor knockdown and inhibition of PG synthesis were also observed in EP3 receptor gene-deficient mutants.
nr2f2 expression in zebrafish at 24 hpf. Therefore, most of the effects of the EP3 receptor on the lymphatic specification might be exerted by the regulation of SOX18 expression. These two transcriptional factors are expressed in the posterior cardinal vein, where embryonic lymphatic development begins. Interestingly, the EP3 receptor was expressed in the region more upstream of the posterior cardinal vein relative to the region of expression of the EP3 receptor, and contributed to lymphatic specification (Fig. 5). Lymphatic vessels develop from endothelial cells in the posterior cardinal vein. Therefore, normal development of the posterior cardinal vein is important for lymphatic vessel development. Our data using RT-qPCR and WISH analyses indicated that the expression levels of FLT4, used as a maturation marker of venous endothelial cells, were not altered in EP3 receptor morphants at 24 hpf, when the posterior cardinal vein is fully developed (Fig. 3 and data not shown). Our observation in Tg(fli1a:egfp) zebrafish also showed that the posterior cardinal vein of EP3 receptor morphants was similar to that of control morphants at both 24 and 36 hpf (data not shown). Additionally, lymphatic vessel development was not impaired by the inhibition of PG synthesis from 12 to 24 hpf, when the posterior cardinal vein develops (Fig. 2A). These data indicated that the EP3 receptor does not affect the development of PCV, at least on evaluation of lymphatic development. However, further detailed studies are needed to precisely determine whether the PGE2-EP3 pathway is involved in the differentiation and/or maturation of the posterior cardinal vein, at a level at which there is no effect on lymphatic development.

We found that the EP3 receptor plays important roles in the expression levels of SOX18 and nr2f2 (Fig. 3). These genes are transcriptional factors that facilitate the lymphatic specification. It was reported that SOX18 genetically interacts with Vegfc in the early phase of lymphatic development, and that SOX18 is required for the expression of nr2f2 in zebrafish at 24 hpf. Therefore, most of the effects of the EP3 receptor on the lymphatic specification might be exerted by the regulation of SOX18 expression. These two transcriptional factors are expressed in the posterior cardinal vein, where embryonic lymphatic development begins. Interestingly, EP3 receptors were found to be expressed in the posterior cardinal vein and the neighboring ICM (Fig. 4). These results suggested that the functions of the EP3 receptor in lymphatic specification were exerted directly (in the posterior cardinal vein) or indirectly (by certain secreted or plasma membrane-associated factors supplied from the adjacent ICM through a paracrine or juxtacrine route).

In this study, we showed for the first time that the PGE2-EP3 pathway plays an essential role in embryonic lymphatic development, by regulating the lymphatic specification, which is the first step of embryonic lymphatic development (Figs 1, 2, 5, 6). We found that the EP3 receptor is important for the expression of sox18 and nr2f2 but not for vegfc, flt4, apln, ccbe1, wnt5b, and bmp2b (Fig. 3). The EP3 receptor was expressed in the posterior cardinal vein and the neighboring ICM (Fig. 4). On the other hand, COX1, but not two COX2 subtypes, was expressed in the region more upstream of the posterior cardinal vein relative to the region of expression of the EP3 receptor, and contributed to lymphatic specification (Fig. 5). Lymphatic vessels develop from endothelial cells in the posterior cardinal vein. Therefore, normal development of the posterior cardinal vein is important for lymphatic vessel development. Our data using RT-qPCR and WISH analyses indicated that the expression levels of FLT4, used as a maturation marker of venous endothelial cells, were not altered in EP3 receptor morphants at 24 hpf, when the posterior cardinal vein is fully developed (Fig. 3 and data not shown). Our observation in Tg(fli1a:egfp) zebrafish also showed that the posterior cardinal vein of EP3 receptor morphants was similar to that of control morphants at both 24 and 36 hpf (data not shown). Additionally, lymphatic vessel development was not impaired by the inhibition of PG synthesis from 12 to 24 hpf, when the posterior cardinal vein develops (Fig. 2A). These data indicated that the EP3 receptor does not affect the development of PCV, at least on evaluation of lymphatic development. However, further detailed studies are needed to precisely determine whether the PGE2-EP3 pathway is involved in the differentiation and/or maturation of the posterior cardinal vein, at a level at which there is no effect on lymphatic development.

In this study, we found that COX1-derived PGE2 accelerated the lymphatic specification during embryonic lymphatic development (Fig. 5), and the EP3 receptor had no effect on the expression levels of vegfc and flt4 (Fig. 3). In contrast to our study, COX2-derived PGE2 was reported to accelerate lymphangiogenesis through the EP3 receptor in tumor implantation and granulation formation models. Mice and human cells were used in these models and PGE2 upregulated the expression of Vegfc and Flt4 through the EP3 receptor. Although the
Figure 6. Effect of EP3 receptor deficiency on lymphatic specification and development. (A) Sequence alignment of the wild-type and mutant EP3 receptor. The seven base-pair deletion in mutant EP3 receptor is indicated by a dotted line. Transmembrane (TM) regions of the wild-type EP3 receptor are indicated by gray boxes. (B) Number of live births of EP3+/+, EP3+/-, and EP3-/- zebrafish. (C) HeLa cells were transfected with an expression vector encoding either the wild-type or mutant EP3 receptor. After 24 h, cells were incubated with loading buffer for 1 h and then treated with Veh or Sulp. Induced intracellular Ca2+ mobilization was evaluated by AUC analysis. *P < 0.05, **P < 0.01 vs Veh. Each value represents the mean ± SEM (N = 3). (D) Relative expression levels of lyve1b were quantified by RT-qPCR in EP3+/+, EP3+/-, and EP3-/- zebrafishs at 24 hpf. Values are shown relative to the value obtained with EP3+/+. Each value represents the mean ± SEM (N = 8–12) *P < 0.05 vs EP3+/+. (E) Expression of lyve1b was analyzed by WISH in EP3+/+, EP3+/-, and EP3-/- zebrafish at 36 hpf. (F) Expression of lyve1b was analyzed by WISH in EP3+/+ and EP3-/- zebrafish at 52 hpf. The PL is indicated by an arrowhead. The number at the bottom right of each panel indicates the number of embryos demonstrating the phenotype shown in the panel over the total number of embryos analyzed in a representative experiment.
reason for these differences is unclear, a likely explanation is that these discrepancies may be owing to differences of venous endothelial cell types among species and tissues, and differences between embryos and adults. Additionally, the different results might be explained by the absence or presence of inflammation. In tumor implantation and granulation formation models, inflammation was induced and immune cells invaded the tissues. It has been reported that migrated macrophages produce VEGFc through the PGE$_2$-EP3 pathway in granulation formation models$^{25,26}$. On the other hand, there have been no reports stating that immune cells are involved in embryonic lymphatic development, particularly in lymphatic specification. Sox18 was reported to be critical for tumor-induced lymphangiogenesis$^{45}$. It is therefore possible that the PGE$_2$-EP3 pathway might promote lymphangiogenesis in tumors and granulation tissues by the upregulation of not only VEGFc and Flt4 expression but also Sox18 expression.

In summary, we found that the PGE$_2$-EP3 pathway plays crucial roles in the lymphatic specification from venous to lymphatic endothelial cells through the upregulation of sox18 and nr2f2. These data strongly suggest a novel function of COX1-PGE$_2$-EP3 pathway in the formation of the lymphatic system during early development.

**Materials and Methods**

**Materials.** The following materials were obtained from the sources indicated; PGE$_2$, sulprostone, and SC-560 from Cayman Chemical (Ann Arbor, MI), indomethacin from Sigma-Aldrich (St. Louis, MO), Calcium 5 Assay Kit from Molecular Devices (Sunnyvale, CA), LightCycler 480 SYBR Green I Master and blocking reagent from Roche Diagnostics (Mannheim, Germany). The EP-specific agonists, ONO-AE1-259 (EP2) and ONO-AE1-329 (EP4), were generous gifts from Ono Pharmaceutical Co. (Osaka, Japan). All other chemicals were commercial products of reagent grade.

**Zebrafish line and maintenance.** A wild-type zebrafish strain was obtained from National BioResource Project Zebrafish (RIKEN, Japan). The transgenic zebrafish line Tg(fli1a:egfp) has been described previously$^{27,32}$, and was used to monitor lymphatic development. Zebrafish were maintained at 28.5 °C under a 14 h-light/10 h-dark cycle. Embryos were maintained in 1/3 ringer solution buffer at 28.5 °C. All experimental protocols were approved by Kumamoto University (24-060, F29-195). All experiments with zebrafish were performed in accordance with the guidelines of Kumamoto University.

**Morpholino antisense oligos.** EP3 MO1 (targeting the splice site between exon 1 and intron 1), EP3 MO2 (targeting the splice site between intron 1 and exon 2), and Cont MO were purchased from Gene Tools, LLC (Philomath, OR). Each MO (10 ng) was injected into the yolk of 1–2 cell stage embryos. The sequence of each MO is shown in Supplementary Table S1.

**RNA extraction and RT-qPCR.** Total RNA was extracted from zebrafish embryos at the indicated stages using Sepasol RNA I Super G (Nacalai Tesque, Kyoto, Japan), and was subjected to RT with PrimerScript RT Master Mix (Takara Bio, Shiga, Japan). Reverse transcription (Roche Applied Science, Penzberg, Germany) and Fast Start DNA Master SYBR Green I according to the manufacturer’s instructions. Crossing point values were acquired by the second derivative maximum method. The expression level of each gene was quantified using external standardized dilutions. Relative expression levels among samples were normalized by the value of gapdh. Sequences of the used primers are shown in Supplementary Table S2. The specificity of qPCR was confirmed by the lengths and melting temperatures of the amplified products.

**Whole-mount in situ hybridization.** Total RNA was isolated from zebrafish embryos, and cDNA was synthesized using SuperScript III (Invitrogen, San Diego, CA) and oligo (dT) primers. The coding sequence of each gene (lyve1b, nr2f2, hey2, and flt4) were amplified from the cDNA by PCR and cloned into the pT2a vector (Toyobo, Osaka, Japan). Primer sequences used in the PCR are shown in Supplementary Table S3. Cloning of the coding sequences of gata1a, the EP3 receptor, COX1, COX2a, and COX2b was performed as previously described$^{30,41}$. These plasmids were linearized by restriction enzymes. Digoxigenin (DIG)-labeled anti-sense RNA was transcribed from each linearized vector by in vitro transcription using DIG mix and transcription buffer (Roche Diagnostics). These RNA was purified by ethanol precipitation, dissolved in hybridization buffer (50% formamide, 5 × SSC, 5 mM ethylenediaminetetraacetic acid, 0.1% Tween-20, and 1 mg/mL torula RNA), and used as hybridization probes. WISH was performed as previously described$^{41}$. After fixation by 4% paraformaldehyde, zebrafish embryos at 52 hpf were incubated in 3% hydrogen peroxide solution to remove dark pigments. Embryos stained with WISH were embedded in OCT Compound (Sakura, Tokyo, Japan) and transverse sections (10–20 μm) were prepared using a cryostat (Leica Microsystems, Wetzlar, Germany). Images were taken with a fluorescence microscope (BZ-X700; KEYENCE, Osaka, Japan) and were processed using the attached software or Adobe Photoshop (Adobe, San Jose, CA).

**Generation of EP3 receptor-mutant zebrafish.** TALEN plasmids were constructed using a two-step assembly system, as described previously$^{43}$. Briefly, six or fewer TAL effector repeat domains were ligated into the pFUS vector$^{43}$. Subsequently, each pFUS vector and last TAL effector repeat were ligated into the pCS2 vector as a TALEN plasmid$^{44}$. The TALEN plasmids were linearized by Not I digestion, and TALEN mRNA was transcribed using the mMESSAGE mMACHINE SP6 kit (Life Technologies, Gaithersburg, MD) and purified using the RNaseasy Mini Kit (QIAGEN, Hilden, Germany). Forward and reverse TALEN mRNA (400 pg each) was simultaneously injected into zebrafish blastomeres at the one-cell stage. To detect genome modification in zebrafish, we utilized the heteroduplex mobility assay as reported previously$^{45}$. The sequences of the primers used in the heteroduplex mobility assay are shown in Supplementary Table S4. To check the functional ability of the TALEN-induced EP3 receptor mutant, the Ca$^{2+}$ mobilization assay was performed using the FLIPR Calcium 5 Assay Kit (Molecular Devices, Sunnyvale, CA) according to the manufacturer’s instructions. Here cells were
grown in modified Eagle’s medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum at 37 °C in a fully humidified CO₂ atmosphere. Wild type or mutant EP3 receptor constructs were transfected into HeLa cells using FuGENE HD (Promega, Madison, WI) according to the manufacturer’s instructions. After 24 h, transfected cells were labeled with calcium 5 loading buffer for 1 h, and stimulated with sulprostone. Fluorescence (excitation, 485 nm; emission, 515 nm) was monitored for 90 seconds on FlexStation III (Molecular Devices) and the area under curve (AUC) was evaluated as induced intracellular Ca²⁺ mobilization.

**Statistical analysis.** Data are shown as the mean ± SEM. Comparison of two groups was analyzed by the Student’s t-test. For comparison of more than two groups with comparable variances, one-way ANOVA was performed, and the Tukey’s test was subsequently used to evaluate the pairwise group difference. P-values less than 0.05 were considered to indicate significant differences.

**References**

1. Tammela, T. & Alitalo, K. Lymphangiogenesis: Molecular mechanisms and future promise. *Cell* **140**, 460–476 (2010).
2. Kohowska, K., Betterman, K. L., Harvey, N. L. & Hogan, B. M. Getting out and about: the emergence and morphogenesis of the vertebrate lymphatic vasculature. *Development* **140**, 1857–1870 (2013).
3. Semu, J., Nicenboim, J. & Yaniv, K. Development of the lymphatic system: new questions and paradigms. *Development* **143**, 924–935 (2016).
4. Küchler, A. M. et al. Development of the zebrafish lymphatic system requires VEGFC signaling. *Curr. Biol.* **16**, 1244–1248 (2006).
5. Hogan, B. M. et al. VEGFc/Flt4 signaling is suppressed by Dll4 in developing zebrafish intersegmental arteries. *Development* **36**, 4001–4009 (2009).
6. Le Guen, L. et al. Ccb1 regulates Vegfc-mediated induction of Vegfr3 signaling during embryonic lymphangiogenesis. *Development* **141**, 1239–1249 (2014).
7. Shin, M. et al. VegFc acts through ERK to induce sprouting and differentiation of trunk lymphatic progenitors. *Development* **143**, 3785–3795 (2016).
8. Aranqure, X. L. et al. Transcription factor COUP-TFI is indispensable for venous and lymphatic development in zebrafish and *Xenopus laevis*. *Biochem. Biophys. Res. Commun.* **410**, 121–126 (2011).
9. Cermenati, S. et al. Sox18 genetically interacts with VegFc to regulate lymphangiogenesis in zebrafish. *Arterioscler. Thromb. Vasc. Biol.* **33**, 1238–124 (2013).
10. Swift, M. R. et al. SoxF factors and Notch regulate nr2f2 gene expression during venous differentiation in zebrafish. *Dev. Biol.* **390**, 116–125 (2014).
11. Lee, S. et al. Prox1 physically and functionally interacts with COUP-TFI to specify lymphoid endothelial cell fate. *Blood* **113**, 1856–1859 (2009).
12. Yamazaki, T., Yoshimatsu, Y., Morishita, Y., Miyazono, K. & Watabe, T. COUP-TFI regulates the functions of Prox1 in lymphatic endothelial cells through direct interaction. *Genes Cells* **14**, 425–434 (2009).
13. Flores, M. V., Hall, C. J., Crosier, K. E. & Crosier, P. S. Visualization of embryonic lymphangiogenesis advances the use of the zebrafish model for research in cancer and lymphatic pathologies. *Dev. Dyn.* **239**, 2128–2135 (2010).
14. Hogan, B. M. et al. Ccb1 is required for embryonic lymphangiogenesis and venous sprouting. *Nat. Genet.* **41**, 396–398 (2009).
15. Kim, J. D. et al. Essential role of Apelin signaling during lymphatic development in zebrafish. *Arterioscler. Thromb. Vasc. Biol.* **34**, 338–345 (2014).
16. Nicenboim, J. et al. Lymphatic vessels arise from specialized angioblasts within a venous niche. *Nature* **522**, 56–61 (2015).
17. Dunworth, W. P. et al. Bone morphogenetic protein 2 signaling negatively modulates lymphatic development in vertebrate embryos. *Circ. Res.* **114**, 56–66 (2014).
18. Coleman, R. A., Kennedy, L., Humphry, P. P. A., Bunce, K. & Lumley, P. Prostanoids and their receptors. In: *Comprehensive Medicinal Chemistry III*, Eds Hansch, C., Sammes, P. G. and Taylor, J. B. pp. 643–714 (1990).
19. Sugimoto, Y. & Narumiya, S. Prostaglandin E receptors. *J. Biol. Chem.* **282**, 11613–11617 (2007).
20. Coleman, R. A., Smith, W. L. & Narumiya, S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. *Pharmacol. Rev.* **46**, 205–229 (1994).
21. Woodward, D. F., Jones, R. L. & Narumiya, S. International Union of Basic and Clinical Pharmacology. LXXIII: classification of prostanoid receptors, updating 15 years of progress. *Pharmacol. Rev.* **63**, 471–518 (2011).
22. Dieterich, L. C. & Detmar, M. Prostanoid-induced angiogenesis and new drug development. *Adv. Drug Deliv. Rev.* **99**, 148–160 (2016).
23. Kubo, H. et al. Host prostanoglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis. *Biomed. Pharmacother.* **64**, 101–106 (2010).
24. Ogawa, F. et al. Prostanoid induces premetastatic niche in regional lymph nodes. *J. Clin. Investig.* **124**, 4882–4894 (2014).
25. Hosono, K. et al. Roles of prostanoglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation. *Arterioscler. Thromb. Vasc. Biol.* **31**, 1049–1058 (2011).
26. Hosono, K., Isomaka, K., Kawakami, T., Narumiya, S. & Majima, M. Signaling of prostanoglandin E receptors, EP3 and EP4 facilitates wound healing and lymphangiogenesis with enhanced recruitment of M2 macrophages in mice. *Proc Natl Acad Sci USA* **110**, 6102–6107 (2013).
27. Yaniv, K. et al. Live imaging of lymphatic development in the zebrafish. *Nat. Med.* **12**, 711–716 (2006).
28. Grosser, T., Yusuff, S., Chesiks, E., Pack, M. A. & Fitzgerald, G. A. Developmental expression of functional cyclooxygenases in zebrafish. *Proc. Natl Acad. Sci. USA* **99**, 8418–8423 (2002).
29. Ishikawa, T. O., Griffin, K. J., Banerjee, U. & Herschman, H. R. The zebrafish genome contains two inducible, functional cyclooxygenase-2 genes. *Biochem. Biophys. Res. Commun.* **352**, 181–187 (2007).
30. Iwasaki, R. et al. Molecular and pharmacological characterization of zebrafish ‘contractile’ and ‘inhibitory’ prostanoid receptors. *Biochem. Biophys. Res. Commun.* **438**, 353–358 (2013).
31. Tsuge, K. et al. Molecular and pharmacological characterization of zebrafish ‘relaxant’ prostanoid receptors. *Biochem. Biophys. Res. Commun.* **436**, 685–690 (2013).
32. Lawson, N. D. & Weinstein, B. M. In vivo imaging of embryonic vascular development using transgenic zebrafish. *Dev. Biol.* **248**, 307–318 (2002).
33. Chen, D. et al. E-Prostanoid 3 Receptor Mediates Sprouting Angiogenesis Through Suppression of the Protein Kinase A/β-Catenin/Notch Pathway. *Arterioscler. Thromb. Vasc. Biol.* **37**, 856–866 (2017).
34. Zhong, T. P., Rosenberg, M., Mohideen, M. A., Weinstein, B. & Fishman, M. C. Gridlock, an HLH gene required for assembly of the aorta in zebras. *Science* **287**, 1820–1824 (2000).
35. Larson, N. D. et al. Notch signaling is required for arterio-venous differentiation during embryonic vascular development. *Development* **128**, 3675–3683 (2001).
36. Leung, A. C. et al. Characterization of expanded intermediate cell mass in zebrafish chordin morphant embryos. *Dev. Biol.* **277**, 235–254 (2005).
37. North, T. E. et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. *Nature* **447**, 1007–1011 (2007).
38. Christian, M. et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757–761 (2010).
39. Pendeville, H. et al. Zebrafish Sox7 and Sox18 function together to control arterial-venous identity. Dev. Biol. 317, 405–416 (2008).
40. Duong, T. et al. Genetic ablation of SOX18 suppresses tumor lymphangiogenesis and metastasis of melanoma in mice. Cancer Res. 72, 3105–3114 (2012).
41. Hanaoka, R., Katayama, S., Dawid, I. R. & Kawahara, A. Characterization of the heme synthesis enzyme coproporphyrinogen oxidase (CPO) in zebrafish erythropoiesis. Genes Cells 11, 293–303 (2006).
42. Cermak, T. et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39, e82 (2011).
43. Sakuma, T. et al. Efficient TALEN construction and evaluation methods for human cell and animal applications. Genes Cells 18, 315–326 (2013).
44. Dahlem, T. J. et al. Simple methods for generating and detecting locus-specific mutations induced with TALENs in the zebrafish genome. Plos. Genet. 8, e1002861 (2012).
45. Ota, S. et al. Efficient identification of TALEN-mediated genome modifications using heteroduplex mobility assays. Genes Cells 18, 450–458 (2013).

Acknowledgements
We thank T. Sugimoto for technical assistance and continuous support, and Y. Yoshihara, A. Miyake, Y. Hisano, S. Ota, T. Koga, and H. Akiko Popiel for invaluable advice. This work was supported by AMED-CREST, Japan Agency for Medical Research and Development 16gm0710006h0104 (to Y.S.), and by the Grants-in-Aid for Scientific Research 22116003, 15H05905 (to Y.S.), 23590076, 26860040, 18H04886 (to S.T.) from the Ministry of Education, Culture, Sports, Science and Technology, and by the Astellas Foundation for Research on Metabolic Disorders (to S.T.).

Author Contributions
R.I. designed and performed the research and wrote the paper; K.T., K.K., Y.H., T.I., H.H., T.I. and A.K. performed the research; S.T. designed and performed the research and wrote the paper; Y.S. designed the research and wrote the paper.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-44095-5.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019